KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) EBT (2016 - 2026)

Eli Lilly filings provide 18 years of EBT readings, the most recent being $8.9 billion for Q1 2026.

  • On a quarterly basis, EBT rose 156.08% to $8.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $31.1 billion, a 128.86% increase, with the full-year FY2025 number at $25.7 billion, up 102.93% from a year prior.
  • EBT hit $8.9 billion in Q1 2026 for Eli Lilly, up from $8.3 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $8.9 billion in Q1 2026 to a low of $427.2 million in Q3 2023.
  • Median EBT over the past 5 years was $2.5 billion (2023), compared with a mean of $3.6 billion.
  • Biggest five-year swings in EBT: plummeted 72.71% in 2023 and later surged 355.33% in 2025.
  • Eli Lilly's EBT stood at $2.1 billion in 2022, then increased by 19.64% to $2.5 billion in 2023, then skyrocketed by 100.87% to $5.0 billion in 2024, then skyrocketed by 64.07% to $8.3 billion in 2025, then rose by 7.06% to $8.9 billion in 2026.
  • The last three reported values for EBT were $8.9 billion (Q1 2026), $8.3 billion (Q4 2025), and $7.2 billion (Q3 2025) per Business Quant data.